دورية أكاديمية
Advanced treatment for basal cell carcinomas.
| العنوان: | Advanced treatment for basal cell carcinomas. |
|---|---|
| المؤلفون: | Atwood SX; Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California 94305., Whitson RJ; Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California 94305., Oro AE; Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California 94305. |
| المصدر: | Cold Spring Harbor perspectives in medicine [Cold Spring Harb Perspect Med] 2014 Jul 01; Vol. 4 (7), pp. a013581. Date of Electronic Publication: 2014 Jul 01. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cold Spring Harbor Laboratory Press Country of Publication: United States NLM ID: 101571139 Publication Model: Electronic Cited Medium: Internet ISSN: 2157-1422 (Electronic) Linking ISSN: 21571422 NLM ISO Abbreviation: Cold Spring Harb Perspect Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Woodbury, NY : Cold Spring Harbor Laboratory Press, c2011- |
| مواضيع طبية MeSH: | Anilides/*therapeutic use , Antineoplastic Agents/*therapeutic use , Carcinoma, Basal Cell/*drug therapy , Hedgehog Proteins/*antagonists & inhibitors , Pyridines/*therapeutic use , Skin Neoplasms/*drug therapy, Drug Discovery ; Drug Resistance, Neoplasm ; Humans ; Receptors, G-Protein-Coupled/antagonists & inhibitors ; Smoothened Receptor ; Technology, Pharmaceutical/trends ; Treatment Outcome |
| مستخلص: | Basal cell carcinomas (BCCs) are very common epithelial cancers that depend on the Hedgehog pathway for tumor growth. Traditional therapies such as surgical excision are effective for most patients with sporadic BCC; however, better treatment options are needed for cosmetically sensitive or advanced and metastatic BCC. The first approved Hedgehog antagonist targeting the membrane receptor Smoothened, vismodegib, shows remarkable effectiveness on both syndromic and nonsyndromic BCCs. However, drug-resistant tumors frequently develop, illustrating the need for the development of next-generation Hedgehog antagonists targeting pathway components downstream from Smoothened. In this article, we will summarize available BCC treatment options and discuss the development of next-generation antagonists. (Copyright © 2014 Cold Spring Harbor Laboratory Press; all rights reserved.) |
| References: | J Med Chem. 2009 Jul 23;52(14):4400-18. (PMID: 19522463) Science. 1997 May 2;276(5313):817-21. (PMID: 9115210) Cancer Lett. 2013 Mar 1;330(1):22-32. (PMID: 23200667) N Engl J Med. 2009 Sep 17;361(12):1164-72. (PMID: 19726763) Science. 2009 Oct 23;326(5952):572-4. (PMID: 19726788) Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13432-7. (PMID: 20624968) N Engl J Med. 2012 Jun 7;366(23):2233-4. (PMID: 22670922) Leuk Res. 2012 Jun;36(6):742-8. (PMID: 22398221) Genes Dev. 2004 Nov 15;18(22):2724-9. (PMID: 15545630) N Engl J Med. 2012 Jun 7;366(23):2180-8. (PMID: 22670904) Clin Cancer Res. 2011 May 15;17(10):3378-87. (PMID: 21558397) J Clin Invest. 2011 May;121(5):1681-3. (PMID: 21519146) Cancer Cell. 2011 Jan 18;19(1):114-24. (PMID: 21215705) Biochem J. 2010 Oct 15;431(2):245-55. (PMID: 20704563) Semin Cutan Med Surg. 2011 Dec;30(4 Suppl):S14-8. (PMID: 22177102) J Clin Invest. 2011 May;121(5):1768-81. (PMID: 21519145) Nat Rev Drug Discov. 2011 Jan;10(1):47-60. (PMID: 21193867) J Cell Biol. 2010 Oct 18;191(2):415-28. (PMID: 20956384) Clin Cancer Res. 2011 Apr 15;17(8):2502-11. (PMID: 21300762) Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60. (PMID: 17494766) Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3438-43. (PMID: 10725363) Dev Biol. 2003 Mar 15;255(2):238-48. (PMID: 12648487) Nat Rev Cancer. 2008 Oct;8(10):743-54. (PMID: 18813320) Cancer Cell. 2010 Apr 13;17(4):388-99. (PMID: 20385363) Nature. 2012 Jun 28;486(7404):537-40. (PMID: 22722843) J Invest Dermatol. 2011 Aug;131(8):1735-44. (PMID: 21430703) N Engl J Med. 2012 Jun 7;366(23):2171-9. (PMID: 22670903) Genes Dev. 2002 Nov 1;16(21):2743-8. (PMID: 12414725) Nat Cell Biol. 2010 Mar;12(3):299-305. (PMID: 20154679) Sci Transl Med. 2010 Sep 29;2(51):51ra70. (PMID: 20881279) Cancer Res. 2011 Jan 15;71(2):435-44. (PMID: 21123452) Can J Biochem. 1966 Jun;44(6):819-28. (PMID: 5919283) N Engl J Med. 2011 Apr 21;364(16):1533-43. (PMID: 21506742) Annu Rev Cell Dev Biol. 2011;27:513-37. (PMID: 21801010) Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4093-8. (PMID: 21321207) Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14132-7. (PMID: 19666565) Nature. 2013 Feb 28;494(7438):484-8. (PMID: 23446420) Oncologist. 2013;18(2):163-73. (PMID: 23340005) Genes Dev. 2010 Apr 1;24(7):670-82. (PMID: 20360384) ACS Med Chem Lett. 2011 Dec 21;3(2):106-11. (PMID: 24900436) Nature. 2012 Jun 28;486(7404):532-6. (PMID: 22722830) Nature. 2003 Nov 6;426(6962):83-7. (PMID: 14603322) Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4505-10. (PMID: 16537363) Cancer Cell. 2013 Jan 14;23(1):23-34. (PMID: 23291299) Bioorg Med Chem Lett. 2009 Oct 1;19(19):5576-81. (PMID: 19716296) Cancer Cell. 2012 Mar 20;21(3):374-87. (PMID: 22439934) Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4099-104. (PMID: 21321199) J Biol Chem. 2010 Aug 20;285(34):26570-80. (PMID: 20504762) Genes Dev. 2008 Sep 15;22(18):2454-72. (PMID: 18794343) Chem Biol. 2011 Apr 22;18(4):432-7. (PMID: 21513879) Nat Med. 2009 Sep;15(9):1055-61. (PMID: 19701205) Dev Cell. 2012 May 15;22(5):940-51. (PMID: 22595669) Nature. 1996 Oct 3;383(6599):407-13. (PMID: 8837770) ChemMedChem. 2008 Dec;3(12):1810-38. (PMID: 18972468) Oncogene. 2010 Sep 2;29(35):4885-95. (PMID: 20603613) Clin Cancer Res. 2012 May 1;18(9):2429-35. (PMID: 22415315) Mol Cancer Ther. 2012 Jan;11(1):165-73. (PMID: 22027695) Arch Dermatol. 2012 Nov;148(11):1324-5. (PMID: 22910979) Proc Natl Acad Sci U S A. 2012 May 15;109(20):7859-64. (PMID: 22550175) Am J Transplant. 2012 May;12(5):1146-56. (PMID: 22420843) N Engl J Med. 2005 Nov 24;353(21):2262-9. (PMID: 16306523) Clin Cancer Res. 2012 Mar 1;18(5):1291-302. (PMID: 21868763) J Cell Biol. 2012 Oct 15;199(2):193-7. (PMID: 23071148) |
| معلومات مُعتمدة: | R01AR052785 United States AR NIAMS NIH HHS; R01 AR054780 United States AR NIAMS NIH HHS; R01AR046786 United States AR NIAMS NIH HHS; R01 AR046786 United States AR NIAMS NIH HHS; R01 AR052785 United States AR NIAMS NIH HHS |
| المشرفين على المادة: | 0 (Anilides) 0 (Antineoplastic Agents) 0 (Hedgehog Proteins) 0 (HhAntag691) 0 (Pyridines) 0 (Receptors, G-Protein-Coupled) 0 (SMO protein, human) 0 (Smoothened Receptor) |
| تواريخ الأحداث: | Date Created: 20140703 Date Completed: 20150330 Latest Revision: 20211021 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC4066644 |
| DOI: | 10.1101/cshperspect.a013581 |
| PMID: | 24985127 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2157-1422 |
|---|---|
| DOI: | 10.1101/cshperspect.a013581 |